• SENSEX 81,603.89
    -192.26 (--0.24%)
  • BANKNIFTY 55,944.90
    417.55 (+0.75%)
  • Vishal Mega Mart
    127.85 134.50(%)
  • Infosys
    1,647.70 2,006.80(%)
  • Sterlite Tech.
    119.00 109.09(%)
  • Varun Beverages
    469.50 419.40(%)
  • HDFC Bank
    1,919.55 1,588.50(%)
  • Reliance Industr
    1,425.80 1,115.55(%)
  • Happiest Minds
    673.90 955.00(%)
  • ICICI Bank
    1,417.60 1,101.00(%)
  • Mazagon Dock
    3,342.85 3,778.00(%)
  • TCS
    3,521.45 4,585.90(%)
  • Garden Reach Sh.
    3,205.00 3,528.00(%)
  • Bharti Airtel
    1,847.50 1,373.05(%)
  • Cochin Shipyard
    2,244.10 2,977.10(%)
  • Tata Motors
    675.00 542.55(%)
  • M & M
    2,993.70 2,360.45(%)
  • Kotak Mah. Bank
    2,155.00 2,301.55(%)
  • Hind. Unilever
    2,334.10 3,034.50(%)
  • Sun Pharma.Inds.
    1,641.40 1,461.40(%)
  • NTPC
    336.85 448.30(%)
  • St Bk of India
    790.75 679.65(%)
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison
Overview
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison

Bafna Pharmaceuticals Ltd Pharmaceuticals - Indian - Formulations

  • Indian Private
  • BSE Code : 28611.0
  • ISIN : INE878I01022
73.18 -1 (-1.72%)
  • As on 17 Jun 2025 (EOD)

  • Today’s Low

    73.17

  • Today’s High

    75.96

  • Open

    74.46

  • Perv Close

    74.46

  • 52W Low

    69.00

  • 52W High

    96.00

Key Indicators

  • P/E(TTM)

    28.57

  • Mar.Cap (₹Cr.)

    173.12

  • Div & Yield %

    0.00

  • Book Value(₹)

    35.85

  • Debt-Equity Ratio

    -1.72

  • AGM Date

    16-Jun-2025

  • EPS

    2.66

  • P/E Ratio

    28.57

Financials Ratios

  • Debt-Equity Ratio

    -

  • Mar.Cap (₹Cr.)

    173.12

  • RONW (%)

    -

  • ROCE (%)

    -

Score Board

  • Equity (₹ in Cr.)

    23.66

  • BV (₹)

    35.80

  • Sales( ₹ in Cr.)

    145.86

  • NP (in Cr.)

    6.30

  • NP Var(%)

    -14.0

  • Div%

    0.0

  • CPS (₹)

    4.70

  • EPS (₹)

    2.70

  • Traded Value (₹ in Lakhs)

    179.79

  • 52 Week High

    96.00

  • 52 Week Low

    69.00

  • Price BSE

    76.0

  • Price NSE

    73.00

  • Market Capital( in Cr.)

    179.79

  • P/C Ratio

    16.10

  • P/E Ratio

    28.50

  • Price Vs.BV

    2.70

View More
Invest Now!

Navigate The Market With Confidence

Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions

Financials

All Values are in (₹Cr)
Particulars(INCOME) 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Mar
INCOME :            
Sales Turnover 152.47 115.35 85.14 71.22 42.47 43.63
Excise Duty 0.00 0.00 0.00 0.00 0.00 0.00
Net Sales 152.47 115.35 85.14 71.22 42.47 43.63
Other Income 3.52 3.27 1.70 0.75 0.26 0.39
Stock Adjustments 4.85 2.91 1.77 -2.95 3.24 -0.81
Total Income 160.84 121.53 88.61 69.02 45.97 43.21
EXPENDITURE :            
Raw Materials 91.58 65.98 41.70 33.58 23.22 27.00
Power and Fuel Cost 6.73 5.31 3.93 2.95 2.69 2.50
Employee Cost 19.03 15.87 14.65 11.98 10.25 9.01
Other Manufacturing Expenses 13.83 8.68 7.72 6.72 5.02 4.48
Selling and Administration Expenses 13.98 5.39 6.92 2.67 3.18 3.13
Miscellaneous Expenses 1.06 1.33 2.19 0.07 23.45 9.77
Employee Benefit Expenses 19.03 15.87 14.65 11.98 10.25 9.01
Less: Preoperative Expenditure 0.00 0.00 0.00 0.00 0.00 0.00
Total Expenses 146.20 102.55 77.11 57.97 67.80 55.89
Operating Profit 14.63 18.99 11.50 11.04 -21.84 -12.68
Interest 2.29 2.04 0.79 0.74 0.10 2.13
Gross Profit 12.34 16.95 10.71 10.30 -21.94 -14.81
Depreciation 5.00 5.33 5.49 4.48 3.27 3.42
Profit Before Tax 7.34 11.62 5.22 5.82 -25.21 -18.23
Current Tax 0.00 0.28 0.00 0.00 0.00 0.00
Fringe Benefit tax 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 1.50
Reported Net Profit 7.35 11.34 5.22 5.83 -25.20 -19.73
Extraordinary Items 0.07 0.20 -2.16 0.00 -23.33 0.00
Adjusted Net Profit 7.28 11.14 7.38 5.83 -1.87 -19.73
Adjustment below Net Profit 0.04 0.15 -0.02 0.00 0.00 0.00
P & L Balance brought forward -54.48 -65.97 -71.17 -76.99 -51.79 -32.06
Statutory Appropriations 0.00 0.00 0.00 0.00 0.00 0.00
Appropriations 0.00 0.00 0.00 0.00 0.00 0.00
P & L Balance carried down -47.10 -54.48 -65.97 -71.17 -76.99 -51.79
Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Preference Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Equity Dividend (%) 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Per Share(Rs) 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Per Share-Unit Curr 3.11 4.79 2.21 2.46 -106.54 0.00
Earnings Per Share(Adj)-Unit Curr 3.11 4.79 2.21 2.46 -106.54 0.00
Book Value 34.17 31.05 26.19 24.00 -18.64 8.79
Book Value(Adj)-Unit Curr 34.17 31.05 26.19 24.00 -18.64 8.79

Shareholding Pattern

  • Promoter Group

    75.00%

  • Public Share Holding

    25.00%

Category of Shareholder No of Shares % Holdings Demat Shares Shareholders
A]. Promoter & Group
Foreign (Promoter & Group) - Bodies Corporate 0 0.00 0 0
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign) 0 0.00 0 0
Foreign Promoter(Institutional) 0 0.00 0 0
Promoter Others 0 0.00 0 0
Sub Total 0 0.00 0 0
[2] INDIAN
Bodies Corporate-Indian (Promoter & Group) 17,640,016 74.57 17,640,016 1
Government(Central / State)-Indian (Promoter & Group) 0 0.00 0 0
Directors & their Relatives-Indian (Promoter & Group) 1,989 0.01 1,989 1
Financial Institutions / Banks-Indian (Promoter & Group) 0 0.00 0 0
Individuals / Hindu Undivided Family-Indian (Promoter & Group) 100,246 0.42 100,246 5
Partnership Firms-Indian (Promoter & Group) 0 0.00 0 0
Persons Acting in Concert 0 0.00 0 0
Trusts 0 0.00 0 0
Others 0 0.00 0 0
Sub Total 17,742,251 75.00 17,742,251 7
Total ShareHolding for Promoter & Group
B]. Publice Share Holding
1] Institution
Government(Central / State) 0 0.00 0 0
Clearing Members 0 0.00 0 0
Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
Financial Institutions / Banks 0 0.00 0 0
Foreign Bank 0 0.00 0 0
Foreign Bodies Corporate/OCBs/FBC 0 0.00 0 0
Foreign Collaborators 0 0.00 0 0
Foreign Institutional Investors 2,018,257 8.53 2,018,257 3
Foreign Venture Capital Investors 0 0.00 0 0
Foreign Institution Other 0 0.00 0 0
Insurance Companies 0 0.00 0 0
Mutual Funds / UTI 0 0.00 0 0
Individuals (Non-Resident / Foreign) 0 0.00 0 0
NSDL Intransit 0 0.00 0 0
Others 0 0.00 0 0
Trusts 0 0.00 0 0
Venture Capital Funds 0 0.00 0 0
Sub total 2,018,257 8.53 2,018,257 3
2] Non Institution
Bodies Corporate 593,999 2.51 593,499 45
Clearing Members 314,530 1.33 314,530 1
Directors of their Relatives 0 0.00 0 0
Employees 0 0.00 0 0
Escrow Account 0 0.00 0 0
Foreign Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
NRIs/Foreign Individuals/Foreign Nationals 184,701 0.78 184,701 70
Foreign Non Institution Other 0 0.00 0 0
Hindu Undivided Families 89,555 0.38 89,555 209
Indian Public 0 0.00 0 0
Individuals holding nominal share capital in excess of Rs. 1 lakh 1,409,653 5.96 1,409,653 13
Individuals holding nominal share capital up to Rs. 1 lakh 1,207,873 5.11 1,201,333 6,789
Market Maker 0 0.00 0 0
NSDL Transit 0 0.00 0 0
Shares in transit 0 0.00 0 0
Societies 0 0.00 0 0
Trust & Foundation 0 0.00 0 0
Others 2,137 0.01 2,137 1
Sub Total 3,895,827 16.47 3,888,787 7,132
Total Public Shareholding
C]. Shares held by Custodians and against which Depository Receipts have been issued
ADR 0 0.00 0 0
GDR 0 0.00 0 0
Other Custodians 0 0.00 0 0
Total Shares held by Custodians and against which Depository Receipts have been issued 0 0.00 0 0
Grand Total ( A + B + C ) 23,656,335 100.00 23,649,295 7,142

Company Background

Bafna Pharmaceuticals LtdPharmaceuticals - Indian - Formulations

  • Bafna Pharmaceuticals Ltd
  • BSE Code : 28611.0
  • ISIN : INE878I01022

  • Incorporation Year

    1995

  • Registered Office

    Bafna Towers New No 68
    Old No 299 Thambu Chetty St, Chennai,
    Tamil Nadu-600001

  • Telephone

    91-44-25267517/25270992/4267755

  • FAX

    91-44-25231264/42677599

  • Chairman

  • Managing Director

  • Company Secretary

    A Mohanachandran

  • Auditor

    Brahmayya & Co

  • Face Value

    10

  • Listing

    NSE

  • Registrar

    Cameo Corporate Services Ltd
    Subramanian Building,
    V Floor,1 Club House Road
    Mumbai - Chennai - 600 002

Bafna Pharmaceuticals Ltd Peer Comparison

Profit & Loss
Financial Ratios
Balance Sheet
Select Company Name LTP (₹) Revenue Sales P/E Ratio ROCE %
Bafna Pharma. 76.00 155.99 152.47 43.18 6.29
Abbott India 31,658.15 6,097.18 5,848.91 47.56 44.71
Astrazeneca Phar 10,204.20 1,330.33 1,295.53 220.39 33.26
P & G Health Ltd 5,907.60 1,166.89 1,151.26 39.04 39.76
Glaxosmi. Pharma 3,366.50 3,866.05 3,723.49 62.06 58.72
Cipla 1,526.90 17,645.00 16,574.34 23.91 20.10
Amrutanjan Healt 700.10 437.58 421.23 39.82 20.84
Guj. Themis Bio. 349.55 174.19 169.82 78.02 44.82
Fermenta Biotec. 341.00 315.24 307.09 14.85 4.10
Bliss GVS Pharma 147.30 638.96 605.46 22.49 11.19
Ambalal Sarabhai 36.91 11.70 3.81 34.18 1.92